Alice Gottlieb, MD, PhD: Previewing the 2025 Masterclasses in Dermatology Meeting

Dr. Gottlieb discusses the upcoming sessions and featured topics being presented at the Masterclasses in Dermatology meeting in Sarasota, Florida.
Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis. Reference:
Emmy Graber, MD, MBA: Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne

Dr. Graber discusses her article published in JCAD January 2025, titled “Prospective Pilot Evaluation of the Safety, Tolerability, and Efficacy of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel plus Clascoterone 1% Cream in Adult Patients with Acne.” Reference:
Naiem T. Issa, MD, PhD: Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series

Dr. Naiem Issa discusses his article published in JCAD January 2025, titled “Real-World Use of Tapinarof Cream 1% Once Daily in Patients with Seborrheic Dermatitis: A Case Series.” Reference: